Tuesday, 28 April 2020

Coronavirus Diagnostics Market to Witness Robust Growth



Surging cases of COVID-19 to drive global coronavirus diagnostics market
Browse 116 market data Figures spread through over 110 Pages and an in-depth TOC on
"Global Coronavirus Diagnostics Market"
The global coronavirus diagnostics market is segmented based on type of test, user, full test time, end user, company and region. Based on type of test, the market can be bifurcated into molecular and serological tests. The serological tests segment is expected to witness significant growth during the forecast period since these tests are done using blood samples. Further, these tests are helpful in determining patients with mild or no symptoms. Based on full test time, the market can be fragmented into less than 60 minutes, 1 hour to 12 hours, 13 hours-24hours and more than 1 days. 1 hour to 12 hourssegment is expected to dominate the market since most of the methods that are available right now take this much duration in the diagnosis of COVID-19 since they involve real time PCR test followed by gene fingerprinting which usually takes time. The less than 60 minutes segment is also expected to witness significant growth during the forecast period because California-based molecular diagnostics company Cepheid has developed a rapid coronavirus diagnostic test with detection time of about 45 minutes and has got the approval from FDA also. By the end of March 2020, the company intends to roll out its testing kits. Based on end user, the market can be segmented into hospitals, public health labs, private or commercial labs, physician labs and others. The hospitals segment is expected to dominate the market owing to the presence of sophisticated diagnostic and treatment facilities in them.
Roche Diagnostics, Abbott, Cepheid Inc, Bio-Rad Laboratories, Beckman Coulter, Becton, Dickinson and Company, Lonza, bioMérieux, Mammoth Biosciences, Hologic, Qiagen, GSK Biologicals, PerkinElmer, Ortho-Clinical Diagnostics, Thermo Fischer Scientific, Mylab, and Altona Diagnosticsare some of the leading players operating in the global coronavirus diagnostics market.The companies operating in the market are increasing focusing on developing low cost diagnostic kits that offer high efficiency and accuracy.For instance, recently Pune (India)based molecular diagnostic company Mylab has become the first Indian company to have received the validation for its COVID-19 diagnostic test kits also known as the Reverse Transcription Polymerase Chain Reaction (RT-PCR) tests by the Drug Controller of India, after the National Institute of Virology validated its test.
Customers can also request for 10% free customization on this report.
“North America and Europe are expected to dominate thecoronavirus diagnostics marketduring the forecast period. Increasing investments in R&D activities along with strong support from the governmentsin the regionsare further expected to create huge market opportunities for diagnostic players over the next few years.”said Mr. Karan Chechi, Research Director with TechSci Research, a research based global management consulting firm.
Global Coronavirus Diagnostics Market By Type of Test, By User, By Full Test Time, By End User, By Region, Competition, Forecast & Opportunities, 2025” has evaluated the future growth potential of global coronavirus diagnosticsmarketand provides statistics &information on market size, structure and future market growth. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges and opportunities in global coronavirus diagnostics market.

3 comments: